Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (31 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Revenue
115
118
127
140
159
205
246
Cost of products sold
33
34
36
38
41
51
63
Amortization of acquired inventory step-up
0
0
0
0
0
2
0
Gross Profit
82
84
92
102
117
151
183
Selling, general and administrative
68
67
71
82
92
128
143
Research, development and other technology
15
15
18
17
22
29
64
Medical device excise tax
0
0
0
0
2
3
3
Acquisition transaction, integration and legal costs
0
0
0
0
0
17
29
Settlement costs license agreement dispute
0
0
2
0
0
0
0
Litigation charge
1
0
1
0
0
0
0
Federal investigation legal and accrued indemnification costs
2
7
0
0
0
0
0
Federal investigation settlement
5
0
0
0
0
0
0
Employee termination and lease abandonment costs
1
2
0
0
0
0
0
Discontinuation costs—Safe-Cross® product line
1
0
0
0
0
0
0
Intangible asset amortization
0
0
0
0
1
6
13
Contingent consideration expense
0
0
0
0
1
2
3
Change in fair value of contingent consideration liability
0
0
0
0
-5
-1
-26
Intangible asset impairment
0
1
0
0
4
4
2
Total operating expenses
94
91
90
99
117
188
233
Operating (loss) income
-12
-7
1
3
0
-37
-51
Interest (expense) income
0
0
0
0
0
-4
-8
Loss on sale of auction rate securities
-1
0
0
0
0
0
0
Other-than-temporary impairment of auction rate securities
-1
0
0
0
0
0
0
Litigation-related interest expense
0
0
0
0
0
0
0
Foreign currency transaction (loss) gain
0
0
0
0
0
0
0
Other income, net
0
0
0
0
0
0
0
Total other (expense) income
-1
0
0
0
0
-4
-8
(Loss) income before income taxes
-13
-7
1
3
0
-41
-59
Income tax expense (benefit)
0
6
0
1
1
0
1
Net loss
-13
-13
1
2
0
-41
-59
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Sep 5, 2014 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (32 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash and cash equivalents
n/a
29
40
38
128
96
85
Investment securities available for sale
n/a
4
0
0
0
0
0
Trade accounts receivable, less allowance for doubtful accounts and sales returns of $1,906 and $1,615, respectively
n/a
16
18
20
27
41
43
Inventories, net
n/a
8
9
9
9
25
25
Deferred income taxes
n/a
0
1
0
0
0
0
Prepaid expenses and other current assets
n/a
2
2
3
3
8
5
Total current assets
n/a
59
69
70
168
170
158
Property and equipment, net
n/a
29
27
27
28
34
45
Debt issuance costs, net
n/a
0
0
0
0
0
0
Goodwill
n/a
6
12
13
15
150
153
Other intangible assets, net
n/a
0
0
0
6
103
110
Other assets
n/a
0
1
1
1
1
2
Total assets
n/a
94
109
111
217
458
468
Liabilities and owners' equity
Borrowings under revolving line of credit
n/a
0 0
0 0
0 0
0 0
0 0
24 24232000
Accounts payable
n/a
1 1392000
2 1521000
2 1996000
3 2587000
4 4397000
4 4150000
Accrued liabilities
n/a
15 14916000
24 24256000
16 16001000
19 18819000
35 35052000
34 33676000
Deferred revenue
n/a
2 2291000
2 2183000
2 2196000
2 1819000
2 1894000
2 1621000
Total current liabilities
n/a
19 18599000
28 27960000
20 20193000
23 23225000
41 41343000
64 63679000
Convertible senior notes, net of debt issuance costs
n/a
0 0
0 0
0 0
0 0
223 223088000
224 224076000
Term loan, net of debt issuance costs
n/a
0 0
0 0
0 0
0 0
0 0
60 59601000
Accrued liabilities, net of current portion
n/a
1 598000
1 706000
1 991000
1 1215000
1 1222000
2 1759000
Contingent consideration, net of current portion
n/a
0 0
0 0
0 0
1 1352000
29 28551000
0 0
Deferred income taxes
n/a
0 0
1 860000
1 888000
1 1365000
1 1477000
2 1915000
Total liabilities
n/a
19 19197000
30 29526000
22 22072000
27 27157000
296 295681000
351 351030000
Commitments and contingencies (Note 14)
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock, $0.001 par value. Authorized 5,000,000 shares; none issued
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Common stock, $0.001 par value. Authorized 120,000,000 shares; issued and outstanding 42,659,234 and 42,060,865 shares, respectively
n/a
0 33000
0 34000
0 35000
0 41000
0 42000
0 42000
Additional paid-in capital
n/a
172 171890000
176 176277000
183 183140000
284 284494000
299 298526000
313 313442000
Accumulated other comprehensive loss
n/a
0 -445000
-1 -715000
-1 -618000
0 -305000
-1 -1280000
-2 -1910000
Accumulated deficit
n/a
-97 -96980000
-96 -96086000
-94 -93860000
-94 -94230000
-135 -135131000
-195 -194605000
Total stockholders’ equity
n/a
74 74498000
80 79510000
89 88697000
190 190000000
162 162157000
117 116969000
Total liabilities and stockholders’ equity
n/a
94 93695000
109 109036000
111 110769000
217 217157000
458 457838000
468 467999000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (42 items missing)
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net loss
-13
-13
1
2
0
-41
-59
Depreciation and amortization
10
10
10
10
11
17
27
Stock-based compensation expense
3
3
2
3
4
8
10
Amortization of debt issuance costs
0
0
0
0
0
1
1
Provision for excess and obsolete inventories
0
0
1
0
0
0
1
Intangible asset impairment
0
0
0
0
4
4
2
Contingent consideration expense
0
0
0
0
1
2
3
Change in fair value of contingent consideration liability
0
0
0
0
-5
-1
-26
Deferred income taxes
0
6
0
0
0
-1
0
Indemnification costs paid
0
6
-3
-3
0
0
0
License agreement settlement
0
0
0
-3
0
0
0
Asset impairment charge
0
1
0
0
0
0
0
Discontinuation costs—Safe-Cross product line, non-cash portion
1
0
0
0
0
0
0
Loss on sale of auction rate securities
1
0
0
0
0
0
0
Other-than-temporary impairment of auction rate securities
1
0
0
0
0
0
0
Trade accounts receivable
-1
0
-3
-2
-6
-6
-3
Inventories
-1
0
-1
-1
0
-3
0
Equipment held for rental or loan, net
-6
-4
-6
-6
-7
-9
-12
Prepaid expenses and other current assets
0
1
-1
0
0
-5
3
Other assets
0
0
0
0
0
0
-1
Accounts payable and accrued liabilities
0
-2
6
4
3
14
-6
Deferred revenue
0
0
0
0
0
0
0
Net cash (used in) provided by operating activities
-5
8
7
5
4
-20
-59
Capital expenditures
-3
-4
-3
-3
-5
-7
-10
Purchase of other intangible assets
0
0
0
0
0
0
0
Decrease in restricted cash
1
1
0
0
0
0
0
Payments for acquisitions
-2
0
0
-8
-7
-234
-30
Proceeds from sale, redemption or maturity of investment securities
11
6
4
0
0
0
0
Purchases of investment securities
0
-1
0
0
0
0
0
Net cash used in investing activities
6
2
2
-11
-11
-241
-40
Proceeds from issuance of convertible senior notes
0
0
0
0
0
230
0
Proceeds from issuance of term loan
0
0
0
0
0
0
60
Proceeds from line of credit, net
0
0
0
0
0
0
24
Debt issuance costs
0
0
0
0
0
-7
0
Net proceeds from stock offering
0
0
0
0
92
0
0
Proceeds from the exercise of stock options and employee stock purchase plan
2
0
2
4
5
6
5
Payment of contingent consideration
0
0
0
0
0
0
0
Net cash provided by financing activities
2
0
2
4
97
228
88
Effect of exchange rate changes on cash
0
0
0
0
0
0
0
Net (decrease) increase in cash and cash equivalents
3
10
10
-2
91
-33
-11
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Feb 26, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Sumo